PRCT PROCEPT BioRobotics Corp Insider Trading

Director Desai Antal Rohit bought 426,262 shares for $10,482,942.95 across 7 transactions at PRCT, now down 61.2% from 52-week high.

Desai Antal Rohit, a Director at PROCEPT BioRobotics, executed 7 separate purchases totaling 426,262 shares for $10,482,942.95 between March 5–9, 2026, at a blended average price of $24.59. The stock is now trading at $25.26, only 2.7% above his average acquisition price, but stands -61.2% below its 52-week high of $65.05 and has declined -27.8% over the past 90 days. Desai's prior track record at PRCT shows 5 consecutive sells in June 2025 that were well-timed at the 90-day mark, all preceding further declines—a pattern suggesting he exits positions before weakness materializes. This substantial purchase into a stock that has lost nearly two-thirds of its recent peak, after proven expertise at identifying sell signals, warrants attention to whether this represents a contrarian conviction or signals internal assessment of value at depressed levels. The company is unprofitable (net income: $-21.4M) against revenue of $83.3M, though it is growing at +37.2% annually.

Director Frederic Moll bought 20,000 PRCT shares at $39.26 on 2025-08-13 (+2.4% of holdings); stock down -30.8% over 30 days and -59.7% from 52-week high.

Frederic Moll, a director at PROCEPT BioRobotics, purchased 20,000 shares ($785.1K) in an open-market transaction, growing his stake by 2.4% to 863.2K shares. The buy occurs against a backdrop of significant recent price pressure: the stock has declined -30.8% over the past 30 days and trades -59.7% below its 52-week high of $99.45. Moll's cross-ticker track record shows strong historical outcomes on buys (4 prior acquisitions averaging +524.1% return over 30 days and +591.5% over 90 days with 100% win rate), though he has not purchased PRCT shares in the measurable history provided. The company itself is growing revenue at +64.8% annually but remains unprofitable, with latest-quarter net income of -$19.6M against $79.2M in quarterly revenue. The confluence of recent weakness and an insider purchase warrants attention to the underlying fundamentals and Moll's conviction in the company's recovery trajectory.

Director Desai sold 75,000 shares (83.9% of holdings) for $4.7M across 8 transactions, leaving 14,363 shares post-sale at blended $62.93 avg price.

Desai, a Director at PROCEPT BioRobotics, executed 8 separate sales totaling 75,000 shares for $4,719,492.35 over three trading days (June 10–12, 2025), reducing his holdings from 89,363 shares to 14,363 shares (an 83.9% reduction). The blended average sale price was $62.93, executed when the stock was trading near recent strength after a 30-day gain of +15.3%. The company reported latest-quarter revenue of $69,162,000.00 but posted a net loss of $-24,737,000.00, with negative full-year net income despite 64.8% annual revenue growth, underscoring continued unprofitability at a $3.4B market cap. His cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 100.00%, but at this specific ticker (PRCT), he has 5 recent prior sales on 2025-06-05 with outcomes not yet measurable, providing no baseline for comparing this sale's positioning relative to his PRCT-specific history.

EVP Shiblaq Hisham sells 20,000 PRCT shares across 3 transactions for $1,282,637.44; prior trade poorly timed as stock rose 12.2% post-sale.

Shiblaq Hisham, Chief Communications Officer, executed three separate sales on 2025-06-06 totaling 20,000 shares (20.0K shares) for $1,282,637.44 (blended average price $64.13), reducing his holdings by -24.1% from 83,133 shares to 63,133 shares. His one prior same-ticker sell at PRCT (2024-06-10) was poorly timed in hindsight: the stock rose 12.2% over the following 90 days, meaning he exited before a gain. The current price of $62.91 is now -36.7% from the 52-week high of $99.45, suggesting material deterioration since his June 2024 sale, though the stock has recovered +18.4% over the last 30 days. PRCT remains unprofitable (net income of -$24.7M on $69.2M quarterly revenue) despite strong annual revenue growth of +64.8%, establishing a backdrop of growth-stage losses that may inform insider perspective on valuation exposure.

Director Desai sold 75,000 shares (45.6% of holdings) for $4.7M on 2025-06-03 to -06-05; PRCT 5-of-5 prior sells well-timed at 90-day mark.

Desai Antal Rohit (Director) executed 13 separate sales totaling 75,000 shares for $4,661,861.00 over June 3–5, reducing his position from 164,363 shares to 89,363 shares. The blended average price across all transactions was $62.16, occurring when the stock was trading in a range from $58.04 to $66.73 and currently sits at $65.05 (down 34.6% from its 52-week high of $99.45). Notably, his prior 5 sales at PRCT all proved well-timed at the 90-day mark, with each generating negative 90-day returns of -21.8% to -25.2%, suggesting a consistent pattern of selling before subsequent declines. The company remains unprofitable (net income $-24.7M on $69.2M quarterly revenue) despite 64.8% annual revenue growth, making near-term price momentum uncertain; the insider's exit of 45.6% of holdings against this backdrop warrants investor attention to whether this signals internal forward-looking concerns.

CEO Zadno Reza sold 15,916 shares at $61.31 on 2025-03-06; stock -42.1% from 52-week high, 5 of 5 prior PRCT sales well-timed.

Zadno Reza (President, CEO) sold 15,916 shares of PRCT at $61.31 on 2025-03-06, reducing holdings by 8.2% to 178,545 shares post-transaction. The stock has declined substantially since the sale: -17.2% over 30 days and -36.8% over 90 days, placing it -42.1% from its 52-week high of $99.45. Notably, his cross-ticker track record shows a 100.00% well-timed rate on 16 prior sales with an average 90-day return of -31.4%, and at this specific ticker (PRCT), all 5 of his prior sales were well-timed, with 90-day post-sale declines ranging from -32.4% to -35.5%. While PRCT reported strong revenue growth of +64.8% annually and generated $58.4M in latest quarterly revenue, the company remains unprofitable with a net loss of $-21.0M over its most recent full fiscal year. The consistent pattern of well-timed sales coupled with deteriorating stock price and company-wide unprofitability warrants close investor attention to fundamentals and forward guidance.

CEO Zadno Reza sells 26,423 shares of PRCT for $2,568,844.46 in four transactions on 2024-12-04

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed four separate sales totaling 26,423 shares for $2,568,844.46 (blended average $97.22) on 2024-12-04, reducing his holdings by 14.7% to 152,762 shares. The sales occurred near the stock's 52-week high of $99.45, with the current price at $94.84 now 4.6% below the high. This comes after Reza's prior sales on 2024-11-27 and 2024-11-20 at the same ticker—five recent transactions within two weeks. The company's fundamentals show revenue of $58,370,000.00 for the latest quarter with significant annual growth of +81.6%, but the company remains unprofitable with net income of -$20,974,000.00 over its most recent full fiscal year. Investors should note the cumulative reduction in CEO holdings in a short window and monitor the company's path to profitability given its current operating losses.

CLO Nouri Alaleh sold 28.1K shares ($2.7M) at $97.13 avg; post-sale holds 52.5K shares at unprofitable PRCT.

Nouri Alaleh, PROCEPT's EVP, CLO, and Corporate Secretary, executed 3 separate sales totaling 28,092 shares for $2,728,573.90 on 2024-12-04, reducing his holdings by 34.9% to 52.5K shares. The sales occurred at prices ($96.12, $96.98, $97.90) near the stock's 52-week high of $99.45, while the company remains unprofitable with a $-21.0M net loss in its latest full fiscal year despite strong 81.6% annual revenue growth. Across his prior 5 open-market sales at PRCT, only 1 of 5 proved well-timed at the 90-day mark, suggesting inconsistent predictive signal; his cross-ticker track record shows 25.00% well-timed rate and average 90d return of +12.1% after sells, indicating sells tend to precede further gains rather than declines. The stock has fallen 4.6% from its 52-week high and is down 3.4% over 30 days, but the transaction's significance is moderate given the mixed historical timing pattern and the company's ongoing profitability challenge.

PRCT CEO Reza sold 26,420 shares for $2.6M at $97.83 avg; 5th sell in 8 days, stock near 52-week high

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed 4 separate sales on November 27, 2024, totaling 26,420 shares (26.4K shares) for $2,584,637.90 ($2.6M) at a blended average price of $97.83. This sale reduced his holdings by 12.8% and marks the fifth insider sell at PRCT in eight days (three sales on November 20, two on November 13). The sales occurred near the stock's 52-week high of $99.27, with the current price at $96.11 now -3.2% from peak. While the company reported strong revenue growth of 81.6% year-over-year, it remains unprofitable with a net income loss of $-20,974,000.00 ($-21.0M) over the latest full fiscal year. The rapid cadence of CEO selling at elevated valuations against the backdrop of continued losses warrants observation of whether this signals portfolio management or changing conviction at a high-valuation, unprofitable growth-stage company.

PRCT CEO Zadno Reza sells 26,420 shares (11.4% of holdings) for $2,445,723.67; stock up 39% in 30 days despite unprofitable fundamentals

Zadno Reza, CEO, executed 3 separate sales totaling 26,420 shares for $2,445,723.67 on 2024-11-20, reducing holdings from 232,025 to 205,605 shares. This follows a pattern of multiple sales at the same ticker over the prior week (5 prior trades at PRCT, with 4 on 2024-11-13 and 1 on 2024-10-30). The timing of these dispositions is notable: the stock has risen 39.0% over the past 30 days and is currently at $93.60, near its 52-week high of $99.07, despite the company reporting a net loss of $20,974,000 on revenue of $58,370,000 in the latest quarter. The concentration of insider selling during a steep price appreciation run, coupled with persistent unprofitability despite 81.6% annual revenue growth, suggests the CEO may be capitalizing on elevated valuations rather than signaling renewed confidence in the business fundamentals.